Navigation Links
Biolex presents Locteron US Phase 2a hepatitis C data at EASL
Date:4/24/2009

Biolex Therapeutics, Inc. announced that the results from its United States Phase 2a clinical trial (the "PLUS" trial) of Locteron will be presented today at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark. Locteron, controlled-release interferon alpha 2b, is designed to improve patient care by providing a more convenient once-every-two week dosing schedule and by reducing the side effects, including flu-like symptoms, associated with pegylated interferons, the current standard of care. Biolex announced earlier this week the commencement of patient dosing in the SELECT-2, a Phase 2b trial of Locteron in the United States and Europe.

The PLUS Phase 2a clinical trial was conducted in 32 chronic hepatitis C patients in the United States who had failed prior treatment. The PLUS trial was designed to evaluate the safety and tolerability of Locteron, and to directly compare Locteron with pegylated interferon. Patients were randomized to receive either Locteron (administered once every two weeks) or PEG-Intron (administered once per week). The Locteron doses evaluated in the PLUS trial include 320 μg, the lowest dose to be evaluated in the SELECT-2 trial, and 640 μg, the highest dose of Locteron evaluated to date. All patients also received oral, weight-based ribavirin. Patients were treated for four weeks with an additional two weeks of follow up evaluation.

Flu-like symptoms were reported to be less frequent and milder in both of the Locteron cohorts of the PLUS trial. The total severity score for flu-like symptoms for patients in the 320 g cohort of Locteron was 80 percent lower than the severity score for the PEG-Intron control cohort (severity score was based on number of occurrences adjusted for severity rating of adverse event). The total severity score for patients in the 640 g cohort of Locteron was 30 percent lower than the severity score for the PEG-Intron cohort. Injections site reactions and common hematological parameters among both of the Locteron cohorts and the PEG-Intron cohorts were comparable. Anti-viral effects were comparable among the Locteron and PEG-Intron cohorts, although three of the four patients achieving undetectable virus were in the 640 g cohort.

"The PLUS trial clearly met its objectives and sets the stage for extended evaluation of Locteron in larger patient populations," said Eric Lawitz, MD, Alamo Medical Research, San Antonio, Texas, lead author on the trial. "As the treatment for hepatitis C evolves there continues to be a need for a next-generation interferon that can improve patient compliance through a combination of improved tolerability and convenience."

Locteron is an investigational therapeutic candidate and has not been approved for sale by the United States Food and Drug Administration or by any international regulatory agency.

Locteron Overview

Locteron is a controlled-release interferon alpha designed to improve patient care in the treatment of hepatitis C through a more favorable side-effect profile and dosing convenience compared to existing pegylated interferon products. In contrast to Locteron's controlled-release mechanism, the currently approved products, Pegasys and PEG-Intron, and the investigational product Albuferon, are immediate-release products that lack a controlled-release mechanism. Interferon alpha serves as the foundation of current combination therapy for hepatitis C patients, and all major hepatitis C drug candidates currently in clinical trials are being studied in combination with interferon alpha. It is estimated that worldwide sales of interferon products for the treatment of hepatitis C will approach $6 billion by 2016.

Locteron combines BLX-883, a recombinant interferon alpha produced by Biolex in its patented LEX SystemSM, with PolyActive, an advanced controlled-release drug delivery technology developed by OctoPlus N.V. of Leiden, the Netherlands. Locteron is configured to allow dosing once every two weeks, more convenient than Pegasys and PEG-Intron, each of which require dosing every week. More importantly, Locteron's controlled-release mechanism results in the gradual release of interferon alpha 2b to patients over the duration of two weeks and avoids the early peak plasma levels of the active interferon that characterize the pegylated interferons and Albuferon. This controlled-release mechanism is designed to reduce the frequency, duration and severity of side effects, including flu-like symptoms, commonly experienced by patients treated with pegylated interferons and with Albuferon. The Company has completed three clinical trials of Locteron, and a Phase 2b trial is currently ongoing in 100 chronic genotype-1 hepatitis C patients in the United States and Europe.


'/>"/>

Contact: Michelle Linn
linnmich@comcast.net
508-362-3087
Linnden Communications
Source:Eurekalert

Related biology news :

1. GSA special paper presents new studies of Western US earth motion
2. AIUM Presents 2009 Joseph H. Holmes Pioneer Awards
3. AIUM presents 2009 Memorial Hall of Fame awards
4. AIUM presents 2009 Distinguished Sonographer award
5. AIUM presents 2009 William J. Fry Memorial Lecture award
6. Stevens Center for Science Writings presents: Ravens at the Feast, with Bernd Heinrich, April 1
7. Understanding soil carbon sequestration: New book presents key concepts
8. World Congress on Osteoporosis 2010 presents outstanding scientific program
9. New manual presents robust, state-of-the-art proteomics methods for teaching and research
10. Arbor Vita presents new data on cancer diagnostic at EUrogin
11. Soil Science Society of America presents awards in Houston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2017)...  Central to its deep commitment to honor ... Japan Prize Foundation today announced the laureates of ... envelope in their respective fields of Life Sciences ... being recognized with the 2017 Japan Prize for ... to the advancement of science and technology, but ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
(Date:1/26/2017)... 2017  Crossmatch, a leading provider of security and ... at combatting fraud, waste and abuse in assistance operations ... Action on Disaster Relief conference in Panama ... agencies and foreign assistance organizations throughout Latin ... are a largely unacknowledged problem in the foreign assistance ...
Breaking Biology News(10 mins):
(Date:2/21/2017)... Orlando, FL (PRWEB) , ... February 21, 2017 ... ... that enables healthcare organizations to build connected digital health applications, announced a partnership ... will enable users to seamlessly connect to many clinical systems while keeping data ...
(Date:2/21/2017)... ... February 21, 2017 , ... Cancer diagnostics workflow solution ... its executive team to lead the development and commercialization of its Cancer Information ... the diagnosis and treatment of cancer. The CIDT addresses the need for curated ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... GMP cell therapy manufacturing facility at its headquarters laboratory in Poway, California. ... utilizing the experience of both in-house personnel and consultants, VetStem constructed and validated ...
(Date:2/21/2017)...  Lexus, a returning partner of the Amgen Tour of ... automobile partner of the men,s and women,s events for the next ... Amgen Tour of California will mark the ... best professional cycling teams in the world racing from Northern to ... Breakaway from Heart Disease TM Women,s Race empowered ...
Breaking Biology Technology: